Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart + Vilzemetkib vs Docetaxel in Advanced NSCLC Post-Immunotherapy
NCT05922345Phase 3Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of benmelstobart and vilzemetkib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Overall Survival up to 36 months. Started Jun 2023; status: recruiting.
02
Drugs
benmelstobartvilzemetkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05922345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05922345.